HUE053745T2 - Helyettesített 5-fluor-1H-pirazolopiridin kristályos formában - Google Patents

Helyettesített 5-fluor-1H-pirazolopiridin kristályos formában

Info

Publication number
HUE053745T2
HUE053745T2 HUE18178621A HUE18178621A HUE053745T2 HU E053745 T2 HUE053745 T2 HU E053745T2 HU E18178621 A HUE18178621 A HU E18178621A HU E18178621 A HUE18178621 A HU E18178621A HU E053745 T2 HUE053745 T2 HU E053745T2
Authority
HU
Hungary
Prior art keywords
pyrazolopyridines
fluoro
substituted
crystalline form
crystalline
Prior art date
Application number
HUE18178621A
Other languages
English (en)
Hungarian (hu)
Inventor
Peter Fey
Alfons Grunenberg
Donald Bierer
Original Assignee
Adverio Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adverio Pharma Gmbh filed Critical Adverio Pharma Gmbh
Publication of HUE053745T2 publication Critical patent/HUE053745T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/26—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
    • C07C303/28—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
    • C07C317/04—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/023—Preparation; Separation; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/037—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements with quaternary ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/067—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HUE18178621A 2011-11-25 2012-11-21 Helyettesített 5-fluor-1H-pirazolopiridin kristályos formában HUE053745T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11190789 2011-11-25
EP11192301 2011-12-07

Publications (1)

Publication Number Publication Date
HUE053745T2 true HUE053745T2 (hu) 2021-07-28

Family

ID=47222101

Family Applications (3)

Application Number Title Priority Date Filing Date
HUE18178621A HUE053745T2 (hu) 2011-11-25 2012-11-21 Helyettesített 5-fluor-1H-pirazolopiridin kristályos formában
HUE12790891A HUE041592T2 (hu) 2011-11-25 2012-11-21 Eljárás szubsztituált 5-fluor-1H-pirazolopiridinek elõállítására
HUE15151593A HUE031029T2 (en) 2011-11-25 2012-11-21 Process for the preparation of substituted (alpha) -fluoro-beta-aminoacrylaldehydes

Family Applications After (2)

Application Number Title Priority Date Filing Date
HUE12790891A HUE041592T2 (hu) 2011-11-25 2012-11-21 Eljárás szubsztituált 5-fluor-1H-pirazolopiridinek elõállítására
HUE15151593A HUE031029T2 (en) 2011-11-25 2012-11-21 Process for the preparation of substituted (alpha) -fluoro-beta-aminoacrylaldehydes

Country Status (42)

Country Link
US (7) US8802847B2 (pt)
EP (3) EP2896617B1 (pt)
JP (4) JP6189315B2 (pt)
KR (3) KR101993022B1 (pt)
CN (3) CN106905314A (pt)
AP (2) AP3898A (pt)
AR (1) AR088983A1 (pt)
AU (3) AU2012342547C1 (pt)
BR (2) BR122020001312B1 (pt)
CA (2) CA2856706C (pt)
CL (2) CL2014001339A1 (pt)
CO (1) CO6960555A2 (pt)
CR (3) CR20190057A (pt)
CU (3) CU24354B1 (pt)
CY (1) CY1124000T1 (pt)
DK (3) DK2896617T3 (pt)
DO (3) DOP2014000112A (pt)
EA (4) EA031602B1 (pt)
EC (1) ECSP14001627A (pt)
ES (3) ES2864009T3 (pt)
GT (1) GT201400101A (pt)
HK (2) HK1203951A1 (pt)
HR (3) HRP20161501T1 (pt)
HU (3) HUE053745T2 (pt)
IL (3) IL232585A0 (pt)
JO (3) JOP20120351B1 (pt)
LT (3) LT2896617T (pt)
MX (1) MX357481B (pt)
MY (3) MY168412A (pt)
PE (3) PE20142359A1 (pt)
PH (2) PH12014501160A1 (pt)
PL (3) PL3421470T3 (pt)
PT (3) PT2896617T (pt)
RS (3) RS61609B1 (pt)
SG (3) SG11201402111QA (pt)
SI (3) SI3421470T1 (pt)
TR (1) TR201816203T4 (pt)
TW (5) TWI659016B (pt)
UA (3) UA120278C2 (pt)
UY (2) UY34467A (pt)
WO (1) WO2013076168A1 (pt)
ZA (2) ZA201403613B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
DE102010043380A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Benzyl-substituierte Carbamate und ihre Verwendung
EA031602B1 (ru) 2011-11-25 2019-01-31 Адверио Фарма Гмбх Способы получения альдегидов
BR112015019571A2 (pt) 2013-02-21 2017-07-18 Adverio Pharma Gmbh formas de {4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo[3,4-b]piridino-3-il]pirimidino-5-il}metilcarbamato de metila
JO3318B1 (ar) 2013-06-18 2019-03-13 Lilly Co Eli مثبطات bace
EA201891416A1 (ru) 2015-12-14 2018-12-28 Айронвуд Фармасьютикалз, Инк. ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ ДИСФУНКЦИИ ЖЕЛУДОЧНО-КИШЕЧНОГО СФИНКТЕРА
EP3554488A2 (en) 2016-12-13 2019-10-23 Cyclerion Therapeutics, Inc. Use of sgc stimulators for the treatment of esophageal motility disorders
KR102615821B1 (ko) 2017-04-11 2023-12-21 선샤인 레이크 파르마 컴퍼니 리미티드 불소-치환된 인다졸 화합물 및 이의 용도
JP2021530491A (ja) 2018-07-11 2021-11-11 サイクレリオン・セラピューティクス，インコーポレーテッド ミトコンドリア（ｍｉｔｏｃｈｏｎｒｉａｌ）障害の処置のためのｓＧＣ刺激剤の使用
TWI830835B (zh) * 2018-12-17 2024-02-01 德商亞德維瑞醫藥有限公司 具改善性質之{4,6-二胺基-2-[5-氟-1-(2-氟芐基)-1H-吡唑並[3,4-b]吡啶-3-基]嘧啶-5-基}胺基甲酸甲酯活性化合物產物、其製造及調配物
WO2020152010A1 (en) 2019-01-22 2020-07-30 Adverio Pharma Gmbh Process for manufacturing 4-(2,2,3,3-tetrafluoropropyl)morpholine
WO2021156223A1 (en) 2020-02-03 2021-08-12 Adverio Pharma Gmbh Nanoformulations of methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
EP3925953A1 (en) * 2020-06-16 2021-12-22 Adverio Pharma GmbH Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
WO2023034364A1 (en) 2021-08-31 2023-03-09 Teva Pharmaceuticals International Gmbh Solid state forms of vericiguat and process for preparation thereof
ES2956054A1 (es) 2022-05-03 2023-12-12 Moehs Iberica Sl 2-(5-FLUORO-1-(2-FLUOROBENCIL)-1H-PIRAZOLO[3,4-b]PIRIDIN-3-IL)-5-NITROSOPIRIMIDIN-4,6-DIAMINA O UNA SAL DE LA MISMA, PROCEDIMIENTO PARA SU PREPARACION Y SU USO EN LA SINTESIS DE VERICIGUAT
CN115043835B (zh) * 2022-06-17 2023-05-09 常州制药厂有限公司 一种维立西呱的精制纯化方法
WO2024038398A1 (en) * 2022-08-18 2024-02-22 Torrent Pharmaceuticals Limited Novel salt of substituted 5-fluoro-1h-pyrazolopyridines and its uses
CN117924280A (zh) * 2024-03-20 2024-04-26 中国人民解放军军事科学院军事医学研究院 取代噻吩基-5-氟-1h-吡唑并吡啶类化合物及其用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8606936D0 (en) * 1986-03-20 1986-04-23 Ici Plc Organic compounds
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
WO1998016507A2 (de) 1996-10-14 1998-04-23 Bayer Aktiengesellschaft Neue heterocyclylmethyl-substituierte pyrazolederivate und ihre verwendung in des behandlung von herz-kreislauf-erkrankungen
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
US6451805B1 (en) 1997-11-14 2002-09-17 Bayer Aktiengesellschaft Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834045A1 (de) 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
EA200100523A1 (ru) 1998-11-16 2001-10-22 Басф Акциенгезельшафт 3-[бенз(окс/ти)азол-7-ил]-1h-пиримидин-2,4-дионы
DE19920352A1 (de) 1999-05-04 2000-11-09 Bayer Ag Substituiertes Pyrazolderivat
DE10057754A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Sulfonamid-substituierte Pyrazolopyridinderivate
AR031176A1 (es) * 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
US6903089B1 (en) 2000-11-22 2005-06-07 Bayer Aktiengesellschaft Lactam-substituted pyrazolopyridine derivatives
DE10131987A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Pyridin-substituierte Pyrazolopyridinderivate
DE10057751A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Carbamat-substituierte Pyrazolopyridinderivate
DE10122894A1 (de) 2001-05-11 2002-11-14 Bayer Ag Neue Sulfonat-substituierte Pyrazolopyridinderivate
KR101011353B1 (ko) 2001-06-22 2011-01-28 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 결정질 항콜린제, 이의 제조방법 및 이를 포함하는 약제학적 조성물
DE10132416A1 (de) 2001-07-04 2003-01-16 Bayer Ag Neue Morpholin-überbrückte Pyrazolopyridinderivate
DE10153737A1 (de) 2001-10-31 2003-05-28 Boehringer Ingelheim Pharma Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
DE10220570A1 (de) * 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE10222550A1 (de) 2002-05-17 2003-11-27 Bayer Ag Substituierte Benzyl-pyrazolopyridine
DE10232571A1 (de) 2002-07-18 2004-02-05 Bayer Ag 4-Aminosubstituierte Pyrimidinderivate
DE10232572A1 (de) 2002-07-18 2004-02-05 Bayer Ag Neue 2,5-disubstituierte Pyrimidinderivate
DE10351903A1 (de) 2003-11-06 2005-06-09 Bayer Healthcare Ag Neue Kombination
DE102006021733A1 (de) * 2006-05-09 2007-11-22 Bayer Healthcare Ag 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung
DE102006031175A1 (de) 2006-07-06 2008-01-10 Bayer Healthcare Ag Wässrige Arzneimittelformulierung von 4-[((4-Carboxybutyl)-(2[(4-phenethyl-benzyl)oxy]-phenethyl)amino)methyl]benzoesäur
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
US20100210644A1 (en) 2007-06-25 2010-08-19 Boehringer Ingelheim International Gmbh Chemical compounds
ES2400104T3 (es) 2007-07-31 2013-04-05 Vertex Pharmaceuticals Incorporated Proceso para preparación de 5-fluoro-1H-pirazolo[3,4-b]piridin-3-amina y derivados de la misma
JP2011513483A (ja) 2008-03-10 2011-04-28 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン
KR100979460B1 (ko) * 2008-05-13 2010-09-02 한국과학기술연구원 함불소알킬그룹이 치환된 이온성 액체의 직접 제조방법
DE102009004245A1 (de) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung
UY33041A (es) * 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
AU2010323227B2 (en) 2009-11-27 2015-11-19 Adverio Pharma Gmbh Method for producing methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate and its purification for use thereof as pharmaceutical substance
UY33040A (es) * 2009-11-27 2011-06-30 Bayer Schering Pahrma Akitengesellschaft Nuevas formas polimorfas de {4,6diamino-2-[1-(2-fluorobencil-1h-pirazol[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
DE102010021637A1 (de) * 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
CN106977530A (zh) 2010-07-09 2017-07-25 拜耳知识产权有限责任公司 环稠合的嘧啶和三嗪以及其用于治疗和/或预防心血管疾病的用途
DE102010040234A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von 5-Flour-1H-pyrazolo[3,4-b]pyridin-3-carbonitril
DE102010040233A1 (de) * 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043380A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Benzyl-substituierte Carbamate und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
EA026701B1 (ru) 2011-09-02 2017-05-31 Байер Интеллектуэль Проперти Гмбх Замещенные аннелированные пиримидины, способ их получения, их применение и лекарственное средство для лечения и/или профилактики заболеваний
EA031602B1 (ru) * 2011-11-25 2019-01-31 Адверио Фарма Гмбх Способы получения альдегидов

Also Published As

Publication number Publication date
EA201491028A8 (ru) 2016-01-29
ES2694158T3 (es) 2018-12-18
EA030018B1 (ru) 2018-06-29
HRP20181818T1 (hr) 2019-01-11
RS61609B1 (sr) 2021-04-29
PL3421470T3 (pl) 2021-08-02
US10364229B2 (en) 2019-07-30
PH12014501160B1 (en) 2014-10-20
CN105503867B (zh) 2019-01-11
MX2014006018A (es) 2014-06-04
AP2015008243A0 (en) 2015-01-31
PT2896617T (pt) 2016-11-18
BR112014012414A2 (pt) 2017-06-06
DK3421470T3 (da) 2021-04-06
CA2856706C (en) 2020-06-16
AR088983A1 (es) 2014-07-23
TWI665198B (zh) 2019-07-11
LT2782914T (lt) 2018-10-10
US9604948B2 (en) 2017-03-28
HK1223613A1 (zh) 2017-08-04
EP2896617A1 (de) 2015-07-22
US8802847B2 (en) 2014-08-12
TW201831447A (zh) 2018-09-01
HRP20210507T1 (hr) 2021-05-28
CA2856706A1 (en) 2013-05-30
CY1124000T1 (el) 2022-05-27
PH12015501494A1 (en) 2015-09-07
UY39646A (es) 2022-04-29
CU20140055A7 (es) 2014-10-02
JOP20210065A1 (ar) 2023-01-30
JP6189315B2 (ja) 2017-08-30
SI2896617T1 (sl) 2016-12-30
CA3040720C (en) 2021-06-15
JOP20120351B1 (ar) 2021-08-17
JP2018058860A (ja) 2018-04-12
HK1203951A1 (en) 2015-11-06
AP3898A (en) 2016-11-16
TR201816203T4 (tr) 2018-11-21
PE20142359A1 (es) 2015-01-09
CN104159898B (zh) 2017-01-18
EP3421470B1 (de) 2021-01-20
DOP2014000112A (es) 2014-07-15
NZ624593A (en) 2016-10-28
SI3421470T1 (sl) 2021-07-30
UA119269C2 (uk) 2019-05-27
LT3421470T (lt) 2021-04-26
WO2013076168A1 (de) 2013-05-30
KR101943788B1 (ko) 2019-01-29
JP2017031180A (ja) 2017-02-09
IL263389B (en) 2022-03-01
ZA201505970B (en) 2017-08-30
TWI631123B (zh) 2018-08-01
TW201708219A (zh) 2017-03-01
MY197904A (en) 2023-07-24
JOP20210064A1 (ar) 2023-01-30
AU2017254916A1 (en) 2017-11-23
ZA201403613B (en) 2016-02-24
IL263389A (en) 2018-12-31
CN105503867A (zh) 2016-04-20
EA201690521A1 (ru) 2016-06-30
CL2014001339A1 (es) 2014-10-17
US20140315926A1 (en) 2014-10-23
CU24354B1 (es) 2018-08-06
AU2012342547B2 (en) 2017-08-17
NZ724215A (en) 2018-03-23
UA120278C2 (uk) 2019-11-11
TWI597280B (zh) 2017-09-01
US20170158652A1 (en) 2017-06-08
TW201838993A (zh) 2018-11-01
EP3421470B8 (de) 2021-08-11
DOP2021000179A (es) 2021-09-30
TWI659016B (zh) 2019-05-11
EP2782914A1 (de) 2014-10-01
MY198086A (en) 2023-07-31
US20190177287A1 (en) 2019-06-13
AU2019202123B2 (en) 2020-09-24
CN106905314A (zh) 2017-06-30
CU24257B1 (es) 2017-05-10
US20180065942A1 (en) 2018-03-08
HUE031029T2 (en) 2017-06-28
CA3040720A1 (en) 2013-05-30
BR112014012414A8 (pt) 2018-01-23
HRP20161501T1 (hr) 2016-12-16
CU20150124A7 (es) 2016-03-31
ES2603028T8 (es) 2021-12-29
EA201491028A1 (ru) 2014-12-30
KR20190018021A (ko) 2019-02-20
TW201329076A (zh) 2013-07-16
DOP2017000013A (es) 2017-02-15
AU2019202123A1 (en) 2019-04-18
BR122020001312B1 (pt) 2022-02-15
AU2012342547C1 (en) 2019-02-21
UA116623C2 (uk) 2018-04-25
PL2782914T3 (pl) 2019-01-31
CO6960555A2 (es) 2014-05-30
KR101993022B1 (ko) 2019-06-25
CN104159898A (zh) 2014-11-19
TW201932465A (zh) 2019-08-16
ECSP14001627A (es) 2015-11-30
EA201690520A1 (ru) 2016-07-29
SG11201402111QA (en) 2014-08-28
ES2603028T3 (es) 2017-02-23
JP6392436B2 (ja) 2018-09-19
SG10201604196VA (en) 2016-07-28
EA201892050A1 (ru) 2019-02-28
GT201400101A (es) 2014-11-13
US20160009671A1 (en) 2016-01-14
CR20210072A (es) 2021-03-22
KR20170130612A (ko) 2017-11-28
EP3421470A1 (de) 2019-01-02
JP2015502932A (ja) 2015-01-29
MX357481B (es) 2018-07-11
ES2864009T3 (es) 2021-10-13
MY168412A (en) 2018-11-09
PH12015501494B1 (en) 2015-09-07
CR20190057A (es) 2019-04-23
AU2017254916B2 (en) 2019-02-28
CL2016000344A1 (es) 2017-02-10
US10633357B2 (en) 2020-04-28
BR112014012414B1 (pt) 2022-01-11
UY34467A (es) 2013-06-28
HUE041592T2 (hu) 2019-05-28
JP2018199698A (ja) 2018-12-20
AU2012342547A1 (en) 2014-06-05
DK2896617T3 (en) 2016-12-12
IL232585A0 (en) 2014-06-30
US10633356B2 (en) 2020-04-28
IL246265A0 (en) 2016-07-31
EP2896617B1 (de) 2016-10-05
US20130143900A1 (en) 2013-06-06
AP2014007705A0 (en) 2014-06-30
SI2782914T1 (sl) 2018-12-31
DK2782914T3 (en) 2018-11-26
US9845300B2 (en) 2017-12-19
SG10201604192XA (en) 2016-07-28
KR20140105483A (ko) 2014-09-01
PH12014501160A1 (en) 2014-10-20
CU20150123A7 (es) 2016-03-31
EP2782914B1 (de) 2018-08-01
PE20190181A1 (es) 2019-02-01
RS55387B1 (sr) 2017-03-31
JP6340391B2 (ja) 2018-06-06
US9150573B2 (en) 2015-10-06
CR20140237A (es) 2014-06-19
EA033455B1 (ru) 2019-10-31
IL246265B (en) 2018-12-31
PT3421470T (pt) 2021-03-31
KR102026059B1 (ko) 2019-09-26
LT2896617T (lt) 2016-12-12
EA031602B1 (ru) 2019-01-31
US20190177288A1 (en) 2019-06-13
NZ721592A (en) 2018-02-23
PT2782914T (pt) 2018-11-16
RS57945B1 (sr) 2019-01-31
PL2896617T3 (pl) 2017-07-31
PE20190180A1 (es) 2019-02-01

Similar Documents

Publication Publication Date Title
PT3421470T (pt) 5-flúor-1h-pirazolopiridinas substituídas na forma cristalina
ZA201309220B (en) Micelle-coated crystalline particles
GB201304499D0 (en) Carcainium Salts
EP2739318A4 (en) INLINE STERILIZER
EP2730619A4 (en) COMPOSITION
EP2943500A4 (en) CRYSTALLINE 3-O-FUCOSYLLACTOSE
HRP20181667T1 (hr) Pripravak
EP2692796A4 (en) COMPOSITION
EP2785766A4 (en) HYDROXYPOLYAMINSALZE
GB201120616D0 (en) Composition
IL231660A0 (en) preparation
GB201119601D0 (en) Composition
HK1201029A1 (en) Composition
GB201121258D0 (en) Composition
SG2014008858A (en) Crystallization methods
GB201108912D0 (en) Composition
GB201103964D0 (en) Composition
GB201204957D0 (en) Composition
GB201115211D0 (en) Composition
GB201216884D0 (en) Composition
LT2726579T (lt) Kompozicija
GB201322023D0 (en) Composition
EP2711011A4 (en) PANAXADIUM-CONTAINING COMPOSITION
GB201118701D0 (en) Composition
GB201118516D0 (en) Composition